Correction of small bowel function as a new direction for treating patients with metabolic syndrome

Vakhrushev Ya.M.

Izhevsk State Medical Academy, Ministry of Health of Russia, Izhevsk, Russia

Lyapina M.V.

Izhevsk State Medical Academy, Ministry of Health of Russia, Izhevsk, Russia

Correction of small bowel function as a new direction for treating patients with metabolic syndrome

Authors:

Vakhrushev Ya.M., Lyapina M.V.

More about the authors

Journal: Therapeutic Archive. 2017;89(8): 43‑49

DOI: 10.17116/terarkh201789843-49

Downloaded: 599

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vakhrushev YaM, Lyapina MV. Correction of small bowel function as a new direction for treating patients with metabolic syndrome. Therapeutic Archive. 2017;89(8):43‑49. (In Russ.)
https://doi.org/10.17116/terarkh201789843-49

Close metadata

Recommended articles:

Predictors of effective complex physiotherapy in patients with skin involution. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):13-20

Serum uric acid — a metabolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42

Assessment of the condition of organs and tissues of the oral cavity in people with dentition defects against the background of metabolic syndrome. Stomatology. 2024;(3):31-38

Human diseases treatment via enema fecal microbiota transplantation. Methodological recommendations. Russian Journal of Preventive Medicine. 2024;(6):79-87

Cognitive behavioral therapy in the treatment of patients with chronic migraine and concomitant chronic insomnia: a prospective, randomized trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):110-117

A personalized application of therapeutic physical factors in patients with metabolic syndrome. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):5-11

Skin alterations as possible clinical markers of diabetes mellitus and metabolic syndrome. Russian Journal of Preventive Medicine. 2024;(7):101-107

Cognitive impairments and emotional disorders and their correction in perimenopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53

Late-onset schizophrenia and schizophrenia-like psychosis with very late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):32-40

Forensic characteristic of sudden death cases in subjects with metabolic syndrome. Forensic Medical Expertise. 2024;(4):54-57

Aim. To provide a rationale for and to evaluate the therapeutic efficiency of the combined use of pancreatic enzymes and actovegin in the combination therapy of patients with metabolic syndrome (MS) on the basis of comprehensive clinical and functional studies of the small bowel (SB). Subjects and methods. In the course of treatment, 120 patients with MS (verified using the diagnostic criteria elaborated by the All-Russian Research Society of Cardiology (2009)) underwent a comprehensive study of SB function: an isolated study of resorptive processes; evaluation of parietal and cavitary digestion, motor-evacuation function. The peripheral blood levels of gastrin, insulin, cortisol, thyroxine and thyrotropin were determined. Results. The combined use of pancreatic enzymes and actovegin has a positive impact on the clinical and functional state of SB, which was manifested as restoration of its hydrolysis and absorption, as well as motor-evacuation function in the patients with MS. The treatment resulted in reductions in the levels of triglycerides from 2.85±0.34 to 1.53±0.18 mmol/l (p<0.01), total cholesterol from 6.08±0.16 to 5.19±0.21 mmol/l (p<0.05), and atherogenic factor from 5.21±0.28 to 2.93±0.34 (p<0.05). Posttreatment HOMA-IR decreased from 4.22±0.8 to 2.12±0.8. There were no substantial changes in insulin levels and insulin resistance index in the patients on standard therapy. Conclusion. The combined use of pancreatic enzymes and actovegin is pathogenetically sound in correcting SB dysfunctions and may be one of the most effective directions for the treatment of patients with MS.

Keywords:

metabolic syndrome

small bowel function

therapy

Authors:

Vakhrushev Ya.M.

Izhevsk State Medical Academy, Ministry of Health of Russia, Izhevsk, Russia

Lyapina M.V.

Izhevsk State Medical Academy, Ministry of Health of Russia, Izhevsk, Russia

List of references:

Egorova E, Zvenigorodskaya L, Lazebnyk L. Metabolic syndrome is a gastroenterologist position. RMZh. 2005;13(26):1706-1712. (In Russ.).
Vahrushev Y, Volkova A. Differentiated approaches to the treatment of patients with chronic pancreatitis with concomitant metabolic syndrome. Еksperimental’naja i klinicheskaja gastrojenterologija. 2011;(11):33-36. (In Russ.).
Butorova L. Dyslipidemia and pathology of the digestive system. Medicinskij vestnik. 2012;9(586):6-10. (In Russ.).
Parfenov A. Enterology. M .: OOO «Medical information agency»; 2009. (In Russ.).
Vahrushev Y, Lyapina M. Clinical and functional characteristics of small intestine in the metabolic syndrome. Еksperimental’naja i klinicheskaja gastrojenterologija. 2011;(9):26-29. (In Russ.).
Vahrushev Y, Lyapina M. Studying the role of small intestine in the development of metabolic syndrome. Terapevticheskij arhiv. 2012;(12):62-65. (In Russ.).
GFCF experts’ recommendations on the diagnosis and treatment of metabolic syndrome. The second revision. Moscow, 2009. (In Russ.) Available at: http://pharm-spb.ru/docs/lit/Rekomendazi Accessed January 22, 2016..
Smolyaninov A. Treatment of patients with duodenal ulcer combined with coronary heart disease and diabetes drug Aktovegin. Klinicheskaja medicina. 2000;(6):24-28. (In Russ.).
Yavorskaya V, Grebenyuk A. Clinical experience with Actovegin in neurology. M.: 2002;17-19. (In Russ.).
Butov M, Shurpo E, Kuznetsov P et al. Normative values for peripheral elektrical gastroenterokolonography. Terapevticheskij arhiv. 2015; 87(2):45-48. (In Russ.). https://doi.org/10.17116/terarkh201587245-48
Smirnova G, Seluyanov S. Peripheral elektrical gastroenterokolonography in clinical practice. M.: Publishing House «Medpraktika-M», 2009. (In Russ.).
Stupin V. Functional Gastroenterology. Instrumental methods of research. Manual for physicians. M.: Publishing House «Medpraktika-M», 2009. (In Russ.).
Lazebnyk L, Zvenigorodskaya L. Metabolic syndrome and digestive organs. M.: Anaharsis, 2009. (In Russ.).
Avdeev V. Diabetic nephropathy. Farmateka. 2010;(3):46-49. (In Russ.).
Shishkov V. Prospects Aktovegin the drug in patients with metabolic syndrome and prediabetes. Modern understanding of carbohydrate metabolism disorders. Practicing endocrinologist. 2008;2(14):23-31. (In Russ.).
Bansal V, Kalita J, Misra U. Diabetic neuropathy. Postgrad Med J. 2006;82:95-100. https://doi.org/10.1136/pgmj.2005.036137
Schmidt R, Thews G. Human Physiology. V.3. M.: Mir; 1996. (In Russ.).
Lychkova A. Serotonin regulation of motor function of the small intestine. Еksperimen-tal’naja i klinicheskaja gastrojenterologija. 2011;(3):130-135. (In Russ.).
Vakhrusheva NV Vakhrushev AM. Comparative evaluation of the therapeutic efficacy of lactase in the primary and secondary hypolactasia small intestine. Еksperimental’naja i klinicheskaja gastrojenterologija. 2006;(5):59-62. (In Russ.).
Vahrushev Y, Kryuchkova V. Essays on the neurohormonal regulation of the respiratory and digestive systems. Izhevsk; 1993. (In Russ.).
Zimmerman J. Chronic gastritis and peptic ulcer disease. Perm: Publishing house PGMA; 2000. (In Russ.).
Gubergrits N. Exocrine pancreatic insufficiency in diabetes. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;(5):61-67. (In Russ.).

Close metadata